1. Caputo V, Libera M, Sisti, Giuliani B, Diotti RA, Criscuolo E. The initial interplay between HIV and mucosal innate immunity. Front Immunol 2023; 14:1104423. https://doi:10.3389/fim-
mu.2023.1104423
2. Onywera H, Willimson AL, Ponomarenko J, Meiring TL. The Penile Microbiota in Uncircumcised and Circumcised Men: Relationships With HIV and Human Papillomavirus Infections and
Cervicovaginal Microbiota. Front Med 2020; 7: 383. https://doi:10.3389/fmed.2020.00383
3. Majdoul, S, Compton, A.A. Lessons in self-defence: inhibition of virus entry by intrinsic immunity. Nat Rev Immunol 2022; 22:339–352 https://doi.org/10.1038/s41577-021-00626-8
4. Rozman M, Zidovec-Lepej S, Jambrosic K, Babi´c M, Drmi´c HI. Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies.
Pathogens 2023;12(1):92 https://doi.org/10.3390/pathogens12010092
5. Bjorgen JC, Dick JK, Cromarty R, Hart GT, Rhein J. NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics? Front Immunol 2023; 14: 1267774. https://
doi:10.3389/fimmu.2023.1267774
6. Moretti S, Schietroma I, Sberna G,Maggiorella, MT Sernicola, LFarcomeni S, et al. HIV-1–Host Interaction in Gut-Associated Lymphoid Tissue (GALT): Effects on Local Environment and
Comorbidities. Int J Mol Sci 2023; 24: 12193. https://doi.org/10.3390/ijms241512193
7. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364:1943–1954 https://doi:10.1056/NEJMra101187
8. Zila V, Margiotta E, Turoňová B, Müller TG, Zimmerli CE, Mattei S et al. Cone-shaped HIV-1 capsids are transported through intact nuclear pores. Cell 2021; 184(4): 1032-1046.e18, https://
doi.org/10.1016/j.cell.2021.01.025.
9. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 Transmission, by Stage of Infection. J Infect Dis 2008; 198(5): 687–693 https://doi.org/10.1086/590501
10. Huang S-W, Briganti L, Annamalai AS, Greenwood J, Shkriabai N, Haney R, et al. The primary mechanism for highly potent inhibition of HIV-1 maturation by lenacapavir. PLoS Pathog
2025;21(1): e1012862. https://doi.org/10.1371/journal.ppat.1012862
11. Ellwanger JH, Veit TD, Chies CAB. Exosomes in HIV infection: A review and critical look. Infection, Genetics and Evolution 2017; 53: 146–154. http://dx.doi.org/10.1016/j.meegid.2017.05.021
12. Arakelyan A, Fitzgerald, W, Zicari, S, Vanpouille C, Margolis L. Extracellular Vesicles Carry HIV Env and Facilitate Hiv Infection of Human Lymphoid Tissue. Sci Rep 2017; 7:1695 https://
doi.org/10.1038/s41598-017-01739-8
13. Lu L, Wang J, Yang Q, Xie E, Huang Y. The role of CD38 in HIV infection. AIDS Res Ther, 2021; 18:11. https://doi.org!0.1186/s12981-021-00330-6
14. Xiao Q, Yu F, Yan L, Lao X, Liang X, Zhao H et al. The CD4/CD8 ratio is associated with T lymphocyte functions in long term virally suppressed patients with HIV. BMC Infects Dis 2025;
25:76 https://doi.org/10.1186/s12879-025-10469-6
15. Parker Miller E, Finkelstein MT, Erdman MC, Seth PC, Fera, D. A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target. Viruses 2021; 13: 1774. https://doi.
org/10.3390/v13091774
16. Song CB, Zhang LL, Wu, XJ, Fu YJ, Jiang YJ, Shang H et al. CD4+
CD38+ central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART. Transl Med
2020;18:95 https://doi.org/10.1186/s12967-020-02245-8
17. Jain A, Canepa GE, Liou M-L, Fledderman EL, Chapoval AI, Xiao L et al. Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and
viral control. Front Med 2024;11:1342476. https://doi:10.3389/fmed.2024.1342476
18. Munoz MAN, Restrepo C, Benito JM, Rallon N. Elite controllers: A heterogeneous group of HIV-infected patients. Virulence 2020; 11(1): 889–897 https://doi.org/10.1080/21505594.2020.17
88887
19. Mastrangelo A, Banga R, Perreau M. Elite and posttreatment controllers, two facets of HIV control. Curr Opin HIV AIDS. 2022;17(5):325-332. https://doi:10.1097/COH.0000000000000751
20. Gaebler C, Kor S, Allers K, Mwangi D, Perotti M, Hanke K et al. The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous
CCR5 WT/Δ32 allogeneic hematopoietic stem cell transplantation. The 25th International AIDS Conference, AIDS 2024 Abstract:12163, Munich, Germany. https://programme.aids2024.org/
Abstract/Abstract/?abstractid=12163
21. Djataou P, Ngounoue MD, Nkenfou-Tchinda CN, NicoleNM, Elise E, Alineet T et al. Low prevalence of HIV in the northern Cameroon: contribution of some AIDS restriction genes and
potential implications for gene therapy. Front Genet, 2024; 15 Article Number 1447971 https://doi.org/10.3389/fgene.2024.1447971.